TB-500 / TB4 — Peptide Dosing Protocols reference

patient_educationexpert_opinion · status: needs_provider_review

Details

Author: —

Citation: —

Summary (generated — provider review required)

TB-500 Dosing Guide: Protocol, Reconstitution & Safety (2026) Shop Protocols Stacks A–Z Index Email Updates Home Protocols TB-500 Dosing Guide: Protocol, Reconstitution & Safety (2026) Protocol / Research Dosing Guide TB-500 Dosing Guide: Protocol, Reconstitution & Safety (2026) An evidence-based TB-500 protocol guide covering loading and maintenance dosing, reconstitution math, supplies, cycle length, safety, and current FDA/WADA status for this thymosin beta-4 fragment peptide. By Garret Grant · Founder & Lead Researcher · Last reviewed June 2026 · Share Supplier Pick Copy code PEPPAL Copy code PEPPAL Verified Supplier Verified Supplier Peptide Partners TB-500 Supply View Supply Table of Contents View Supplies Quick Start Dosing Protocol & Schedule Supplies Needed Reconstitution Guide Dosage Chart Mechanism Who Should Avoid It Side Effects & Safety Timeline & Monitoring Clinical Evidence Storage & Handling Troubleshooting Regulatory Status TB-500 Comparisons Related Protocols Blood Tests FAQ References TB-500 Quick Start TB-500 is a synthetic 7-amino-acid fragment of thymosin beta-4, a larger peptide found throughout the body. Its sequence is Ac-LKKTETQ , which matches amino acids 17-23 of thymosin beta-4 (Tbeta-4).

The original source document remains the source of truth. Generated summaries are not authoritative.

Linked assets (11) · phenotypes (0)

evidence_reference, dosing_reference, safety_reference, mechanism, monitoring_reference

Findings (154) · awaiting review (120)

regulatory · pending

Q8: Is TB-500 FDA-approved?

safety · pending

For the wider research view, read the TB-500 repair peptide guide on how it works, studies, safety notes, and related peptides.

dosing · pending

By Garret Grant · Founder & Lead Researcher · Last reviewed June 2026 · Share Supplier Pick Copy code PEPPAL Copy code PEPPAL Verified Supplier Verified Supplier Peptide Partners TB-500 Supply View Supply Table of Contents View Supplies Quick Start Dosing Protocol & Schedule Supplies Needed Reconstitution Guide Dosage Chart Mechanism Who Should Avoid It Side Effects & Safety Timeline & Monitoring Clinical Evidence Storage & Handling Troubleshooting Regulatory Status TB-500 Comparisons Related Protocols Blood Tests FAQ References TB-500 Quick Start TB-500 is a synthetic 7-amino-acid fragment of thymosin beta-4, a larger peptide found throughout the body.

dosing · pending

Route Most research-use protocols use subcutaneous injection.

dosing · pending

Concentration A 10 mg vial mixed with 2 mL bacteriostatic water gives 5 mg/mL.

dosing · pending

On a U-100 syringe, 10 units is 0.10 mL, or about 500 mcg.

dosing · pending

Schedule Community protocols typically use a loading phase (twice weekly) followed by a maintenance phase (once weekly).

regulatory · pending

Removed from FDA 503A Category 2 on April 15, 2026; PCAC review scheduled for July 23, 2026 for potential 503A inclusion for wound healing.

dosing · pending

Most of the practical research-use cycle planning for TB-500 (such as 2 mg twice weekly for 4-6 weeks then 2 mg once weekly) is community-derived and not validated by a published human RCT of the TB-500 fragment.

dosing · pending

Treat published cycle ranges as starting reference points for research planning, not personal dosing instructions.

dosing · pending

Adjust syringe draw volumes if planning a lower per-dose amount; BAC-water needs depend on vial count and chosen concentration.

regulatory · pending

TB-500 is not approved by the FDA for human use, is sold for research purposes only, and is on the World Anti-Doping Agency Prohibited List.

dosing · pending

Information about doses, cycles, and reconstitution is research-use planning informat

dosing · pending

Use this protocol for TB-500 dosing, vial mixing, and cycle planning.

safety · pending

The closest human safety reference is a Phase 1 study of full-length thymosin beta-4, not TB-500.

dosing · pending

In that study, healthy volunteers received IV doses ranging from 42 mg to 1260 mg, followed by daily dosing for 14 days, with no dose-limiting toxicities.

dosing · pending

TB-500 Dosing Patterns Two patterns show up most often in research planning: a load-and-maintain schedule and a shorter acute-injury schedule.

dosing · pending

A common research-use plan is approximately 2-2.5 mg subcutaneous twice weekly.

dosing · pending

At 5 mg/mL (10 mg vial in 2 mL), that is 0.4-0.5 mL per dose, or roughly 40-50 units on a U-100 insulin syringe.

dosing · pending

Twice weekly dosing produces about 4-5 mg per week.

dosing · pending

Typical research-use plans drop to approximately 2-2.5 mg subcuta

dosing · pending

neous once weekly for ongoing cycles, or pause and re-evaluate.

dosing · pending

This is not a dosing recommendation.

dosing · pending

Load + Maintenance research-use cycle planning (not a dosing recommendation) Phase Loading Weekly amount ~4-5 mg/week Frequency Twice weekly Duration Weeks 1-6 Phase Maintenance Weekly amount ~2-2.5 mg/week Frequency Once weekly Duration Weeks 7-12 Phase Off period Weekly amount 0 mg Frequency None Duration 4-8 weeks Phase Weekly amount Frequency Duration Loading ~4-5 mg/week Twice weekly Weeks 1-6 Maintenance ~2-2.5 mg/week Once weekly Weeks 7-12 Off period 0 mg None 4-8 weeks These numbers come from community protocol references, not validated human TB-500 trial data.

dosing · pending

A pattern referenced in the community is roughly 2-2.5 mg every 2-3 days for 2 weeks, then 2-2.5 mg once weekly for 4-6 weeks.

dosing · pending

Acute window research-use cycle planning (not a dosing recommendation) Phase Front-loading Per-dose amount ~2-2.5 mg Frequency Every 2-3 days Duration Weeks 1-2 Phase Taper Per-dose amount ~2-2.5 mg Frequency Once weekly Duration Weeks 3-8 Phase Per-dose amount Frequency Duration Front-loading ~2-2.5 m

dosing · pending

g Every 2-3 days Weeks 1-2 Taper ~2-2.5 mg Once weekly Weeks 3-8 Front-loading patterns vary widely between research-use references.

dosing · pending

It must be reconstituted with bacteriostatic water before drawing a dose.

mechanism · pending

Actin sequestration Tbeta-4 binds G-actin monomers and is one of the major regulators of the monomeric actin pool.

dosing · pending

Cycle Guidelines Cycle structure references commonly used in research planning Approach Short cycle Duration 4-6 weeks Off period 4 weeks Best for Single research-question focus Approach Standard cycle Duration 8-12 weeks Off period 4-8 weeks Best for Most community-referenced plans Approach Maintenance after load Duration Once weekly, 6-12 weeks Off period Variable Best for Continuation after a 4-6 week loading phase Approach Duration Off period Best for Short cycle 4-6 weeks 4 weeks Single research-question focus Standard cycle 8-12 weeks 4-8 weeks Most community-referenced plans Maintenance after load Once weekly, 6-12 weeks Variable Continuation after a 4-6 week loading phase There is no published human RCT of the TB-500 fragment establishing an optimal cycle length.

dosing · pending

Evidence boundary The dosing ranges above reflect common research-use references.

dosing · pending

TB-500 Supplies Needed Plan based on the standard load-and-maintenance schedule (about 2.5 mg twice weekly for 6 wee

dosing · pending

ks, then 2.5 mg once weekly).

dosing · pending

Supplies math assumes 10 mg vials reconstituted with 2.0 mL bacteriostatic water (5 mg/mL).

dosing · pending

Peptide Vials Each 10 mg vial reconstituted with 2 mL BAC water = 5 mg/mL.

dosing · pending

About 4 doses of 2.5 mg per vial.

dosing · pending

Cycle length Planning note 4 weeks 2 vials Loading only: 8 doses x 2.5 mg = 20 mg total.

dosing · pending

6 weeks 3 vials Loading: 12 doses x 2.5 mg = 30 mg total.

dosing · pending

8 weeks 4 vials 6-week loading + 2-week maintenance: 14 doses x 2.5 mg = 35 mg total; round up to 40 mg.

Processing

Processed into 28 searchable sections.